The Medicine Maker | The Medicine Maker

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

October 12, 2026

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

8 min read

Cell & Gene

Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce

Facilities & Equipment

This Month’s Manufacturing Moves

Bayer plans a $2.2 billion Ohio campus, Genentech breaks ground in Oregon, and new investments support vaccine production, downstream processing, and manufacturing in orbit

Drug Delivery

Prula-cel Shows Early Promise in Lupus

Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy

Development & Clinical

The Staying Power of Small Molecules

We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins

Cell & Gene Small Molecules Biopharma Future of Pharma

The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.

Our celebration of the most inspirational and influential leaders in medicine.

Find out more

Ann Cleves

VP of Application Science, BioPharmics Division, Optibrium

View Profile

Bruce Levine

Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine

View Profile

Musings from The Power List: Claudia Zylberberg

Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale

Read the article

All the latest Medicine Maker articles.

Outsourcing Cell & Gene Sitting Down With

Video: Sitting Down With… John Tomtishen

October 7, 2026

Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization

1 min read

Cell & Gene Research News

Pregnancy After CAR T Shows Early Promise

October 7, 2026

No autoimmune disease flares occurred across 14 pregnancies after CAR T-cell therapy, with 8 healthy babies born and 5 pregnancies ongoing.

3 min read

Cell & Gene Research News

When CAR T Cells Linger in the Gut

October 7, 2026

Persistent CAR T cells and widespread immune disruption may help explain a rare form of severe intestinal inflammation after BCMA-directed therapy

3 min read

Industry News Future of Pharma Research News

Building a Pre-Disease Data Map

October 7, 2026

Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear

2 min read

Cell & Gene Regulation & Standards Technology & Manufacturing

Building a CAR-T CMC Strategy on a Limited Budget

October 6, 2026

Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes

7 min read

Development & Clinical Biopharma Interviews Power List

Musings from The Power List: Andres Sirulnik

October 5, 2026

Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines

4 min read

Supply Chain Business & Trends

Video: From Accounting to Action on Pharma Sustainability

October 2, 2026

Ahead of CPHI Milan’s Sustainability Summit, Silvia Forroova and Rob Williams discuss how shared standards and supplier partnerships can turn commitments into measurable progress.

1 min read

Supply Chain Future of Pharma Business & Trends Power List

The Resilience Prescription

October 2, 2026

We asked the 2026 Power List how the pharmaceutical industry can prepare for geopolitical, economic, regulatory, and scientific uncertainty

5 min read

Development & Clinical Cell & Gene Interviews Business & Trends Technology & Manufacturing Power List

Musings from The Power List: Fabian Gerlinghaus

October 1, 2026

Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made

3 min read

Cell & Gene Sponsored

In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming

September 30, 2026

How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications

10 min read

Top Stories